Q3 2025 Financial Performance - Net sales reached $178 million, reflecting 10% organic growth[18] - Adjusted EPS stood at $0.36[18] - Adjusted EBITDA amounted to $20 million with an 11% margin[18] Segment Performance - Specialty Nutrition Systems experienced 14.5% organic growth, with net sales of $114 million[20] - Specialty Nutrition Systems operating profit was $23 million, representing a 20% margin[21] - Pain Management & Recovery saw 2.4% organic growth, with net sales of $59 million[26] 2025 Outlook - Net sales are estimated to be between $690 million and $700 million[16, 33] - Adjusted EPS is projected to be between $0.85 and $0.95 per share[16, 33] Financial Position - Cash balance was $70 million as of September 30, 2025[31] - Net debt was $(33) million, with a net debt to EBITDA ratio of approximately 0.4x[31] Strategic Initiatives - Expanded transformation initiatives are expected to deliver $15 to $20 million of incremental annualized savings by the end of 2026[16]

Q1 2025 Financial Performance - Net sales increased to $168 million in Q1 2025 from $166 million in Q1 2024, representing a 2.8% organic growth[19] - Adjusted EPS grew by 18% from $0.22 in Q1 2024 to $0.26 in Q1 2025[19] - The company generated $19 million of free cash flow during the quarter[22] - Net debt decreased to $10 million as of March 31, 2025, compared to $27 million as of December 31, 2024[21] Segment Performance - Specialty Nutrition Systems net sales increased to $101 million in Q1 2025 from $95 million in Q1 2024, reflecting a 9.4% organic growth[27] - Specialty Nutrition Systems operating profit increased by 37% from $15 million in Q1 2024 to $21 million in Q1 2025[29] - Pain Management & Recovery segment net sales remained stable at $56 million in Q1 2025, showing a 1.1% organic growth[33] - Pain Management & Recovery segment operating profit improved from -$2 million in Q1 2024 to $0 million in Q1 2025[34] 2025 Outlook - The company maintains its sales estimate of $665 million to $685 million[44] - The company lowered its adjusted diluted EPS estimate to $0.75 to $0.95, primarily due to tariff impacts[45]